Cargando…
USP8 modulates ubiquitination of LRIG1 for Met degradation
The Met receptor tyrosine kinase is an attractive target for cancer therapy as it promotes invasive tumor growth. SAIT301 is a novel anti-Met antibody, which induces LRIG1-mediated Met degradation and inhibits tumor growth. However, detailed downstream mechanism by which LRIG1 mediates target protei...
Autores principales: | Oh, Young Mi, Lee, Saet Byoul, Choi, Jaehyun, Suh, Hye-Young, Shim, Seonhui, Song, Yun-Jeong, Kim, Bogyou, Lee, Ji Min, Oh, Seung Ja, Jeong, Yunju, Cheong, Kwang Ho, Song, Paul H., Kim, Kyung-Ah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021411/ https://www.ncbi.nlm.nih.gov/pubmed/24828152 http://dx.doi.org/10.1038/srep04980 |
Ejemplares similares
-
Common dental anomalies in Korean orthodontic patients: An update
por: Ku, Ja Hyeong, et al.
Publicado: (2022) -
Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015) -
The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
por: Cheng, Fangling, et al.
Publicado: (2019) -
Soluble LRIG2 is a potential biomarker for type 2 diabetes mellitus
por: Kim, Ji Min, et al.
Publicado: (2021) -
LRIG and cancer prognosis
por: Lindquist, David, et al.
Publicado: (2014)